Therefore, BP variability in both the acute and subacute stages Background and Purpose-The relationship between blood pressure (BP) variability and functional outcome in patients with acute ischemic stroke remains unclear. This study aimed to elucidate whether in-hospital day-by-day BP variability is associated with functional outcome after acute ischemic stroke. Methods-Using the Fukuoka Stroke Registry, we included 2566 patients with a first-ever ischemic stroke who had been functionally independent before the onset and were hospitalized within 24 hours. BP was measured daily, and its variability was assessed by SD, coefficients of variance, and variations independent of mean. Poor functional outcome was assessed by modified Rankin Scale scores ≥3 at 3 months. Results-After adjustment for multiple confounding factors including age, sex, risk factors, stroke features, baseline severity, thrombolytic therapy, antihypertensive agents, and mean BP, day-by-day BP variability during the subacute stage (4-10 days after onset) was independently associated with a poor functional outcome (multivariable-adjusted odds ratios [95% confidence interval] in the top versus bottom quartile of systolic BP variability, 1.51 [1.09-2.08] for SD; 1.63 [1.20-2.22] for coefficients of variance; 1.64 [1.21-2.24] for variations independent of mean). Similar trends were also observed for diastolic BP variability. These trends were unchanged in patients who were not treated with antihypertensive drugs. In contrast, no association was found between indices of BP variability during the acute stage and functional outcome after adjusting for potential confounders. Conclusions-These data suggest that intraindividual day-by-day BP variability during the subacute stage is associated with the 3-month functional outcome after acute ischemic stroke. may have clinical significance in functional outcome after acute stroke. An interval of BP fluctuations used in the previous studies ranged from beat-to-beat, hour-to-hour to day-to-night. However, the clinical significance of BP variability in cardiovascular diseases remains controversial. [14] [15] [16] Determinants and prognostic relevance for cardiovascular outcomes are probably different among short-term (beat-to-beat), short-term (for 24 hours), midterm (day-to-day), and long-term BP variability (visit-to-visit).
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I
n patients with acute stroke, blood pressure (BP) rises in response to apoplexy and then gradually decreases with time to prestroke levels.
1,2 BP level during the acute stage is an important factor that can worsen clinical outcomes after acute stroke. [3] [4] [5] In addition, BP variability may be associated with poor clinical outcomes in patients with stroke. Previous studies reported that reading-to-reading BP fluctuations within the first 24 to 72 hours after ischemic stroke were associated with hemorrhagic transformation 6, 7 and poor outcomes, [7] [8] [9] although no significant association was also reported. 10 BP rapidly falls within the initial 3 days and then gradually declines during the following week. 11 The clinical significance of BP variability has been mainly investigated during the first few days after onset when the patient's condition is unstable and requires intensive care (acute stage). However, there is a paucity of data on the postacute period (subacute stage). Recent studies have suggested that reading-to-reading or day-to-night BP variability in the postacute phase was also a risk factor for poor functional outcome after acute stroke.
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may have clinical significance in functional outcome after acute stroke. An interval of BP fluctuations used in the previous studies ranged from beat-to-beat, hour-to-hour to day-to-night. However, the clinical significance of BP variability in cardiovascular diseases remains controversial. [14] [15] [16] Determinants and prognostic relevance for cardiovascular outcomes are probably different among short-term (beat-to-beat), short-term (for 24 hours), midterm (day-to-day), and long-term BP variability (visit-to-visit). 15 BP fluctuations with longer intervals, including midterm and long-term BP variability, are of increasing clinical interest as predictors of end-organ damage, 17 cardiovascular events, [18] [19] [20] [21] and mortality. 22 A recent study showed a possible association of visit-to-visit BP variability with longterm mortality after lacunar infarct. 23 However, the association between BP variability with a long interval and functional outcome after ischemic stroke is still unknown.
In the present study, we calculated indices of day-by-day BP variability until the subacute stage and investigated their association with short-term clinical outcomes in patients with ischemic stroke registered in the Fukuoka Stroke Registry (FSR). We hypothesized that in-hospital BP variability with a long interval, day-to-day BP variability, may be associated with functional outcome at 3 months after ischemic stroke. The present study aimed to examine the associations between indices of day-to-day BP variability in the acute and subacute periods and 3-month functional outcome after acute ischemic stroke.
Methods
Patient Selection
The FSR is a multicenter, hospital-based prospective registry that includes consecutive patients with acute stroke who were admitted to 7 participating hospitals within 7 days of onset (UMIN-CTR 000000800). 24, 25 Stroke was defined as the sudden onset of a nonconvulsive and neurological deficit persisting for ≥24 hours. Stroke subtypes were confirmed by brain imaging, including computed tomography and magnetic resonance imaging, and ischemic stroke was further classified as lacunar, atherothrombotic, cardioembolic infarction, and unclassified (other determined or undetermined pathogenesis) subtypes. The infarct area responsible for the neurological symptom was categorized into posterior or anterior circulation according to the location identified with computed tomography or magnetic resonance imaging.
Of 7571 patients registered in the FSR prospective database between June 2007 and April 2013, 6927 had ischemic strokes. The present study included patients with a first-ever ischemic stroke who were functionally independent before onset, were admitted to the hospital within 24 hours, and were hospitalized for >10 days. Patients who had stroke recurrence within 10 days of onset and those without recorded modified Rankin Scale scores at 3 months were excluded ( Figure) .
Measurement and Management of BP
Trained nurses measured the BP of patients resting in the supine position using an automated cuff or a mercury or aneroid sphygmomanometer. On the day of onset (day 1), BP was high, but rapidly declined during the acute stage (days 1-3). Thereafter, BP decreased more slowly during the next 7 days (days 4-10, the subacute stage; Figure I in the online-only Data Supplement). To evaluate BP variability during the acute stage, BP was measured during 3 days after admission: day 1, on admission, and at 10:00 AM, 02:00 PM, and 06:00 PM if these times were later than admission and days 2 and 3, 3×/d at 10:00 AM, 02:00 PM, and 06:00 PM. During the subacute stage, BP was measured once per day at 10:00 AM from 4 to 10 days. BP was measured in the same side depending on the patient's conditions, including paralysis and intravenous infusion. BP was managed according to the Japanese Guidelines for the Management of Stroke. 26, 27 BP values with ≥5 measurements were used to calculate the variability indices. After excluding patients with <5 BP measurements during the subacute stage (from 4 to 10 days after admission), 2566 patients were analyzed (Figure) .
problematic to adjust these variables together with mean BP in a multivariable model. Therefore, VIM was developed as a new measure of variability uncorrelated with mean BP. 28 Using nonlinear regression analysis (PROC NLIN) in SAS Version 9.3 (SAS Institute, Cary, NC), VIM was determined by the formula: VIM=M x ×SD/mean x , where M was the average of mean systolic (SBP) or diastolic BP (DBP) among the study subjects, x was derived from fitting curves, and SD=k×mean
x
. VIM showed no significant correlation with mean BP in the present study ( Figure II in the online-only Data Supplement). VIM is a statistical tool, rather than a clinical measure.
28
Clinical Outcomes
Primary and secondary outcomes were poor functional outcome and neurological deterioration, respectively. Functional outcome was evaluated by modified Rankin Scale at 3 months after stroke onset. Information of functional status was collected via direct or telephone interviews with patients, family members, or caregivers. To assess modified Rankin Scale, we used a Japanese guidance scheme and interview questionnaire, in which inter-rater agreement and reproducibility of assessment were satisfactory. 29 Poor functional outcome was defined as moderate-to-severe disability or death with a modified Rankin Scale of ≥3. Neurological deterioration was defined as an increase in the National Institutes of Health Stroke Scale (NIHSS) ≥2 during hospitalization.
Statistical Analysis
Data are shown as mean±SD. Associations between each BP parameter (mean, SD, CV, and VIM of SBP or DBP as a categorical variable based on quartiles) and poor functional outcome were determined using logistic regression analysis. Multivariable model 1 included age and sex. Multivariable model 2 included body mass index, hypertension, diabetes mellitus, dyslipidemia, atrial fibrillation, estimated glomerular filtration rate, ischemic stroke subtype (cardioembolic or noncardioembolic infarction), infarct area (anterior or posterior circulation), antihypertensive agents administered during acute or subacute stage, the baseline severity, and thrombolytic therapy, besides age and sex. Stroke neurologists determined stroke severity on admission and at discharge using the NIHSS. Minor stroke was defined as NIHSS at onset ≤4. Thrombolytic therapy during the hyperacute stage included the intravenous or intra-arterial administration of thrombolytic agents. These covariates were selected by their clinical significance, as we previously reported. 5 Multivariable model 3 included average BP in addition to the factors in model 2. All statistical analyses were performed using SPSS Version 21.0J (SPSS Japan Inc, Tokyo, Japan). Probability values of <0.05 were considered statistically significant. 
Results
Baseline Characteristics
BP Variability and Clinical Outcomes
The association between baseline NIHSS and BP variability indices was first investigated (Table I in the online-only Data Supplement). CV and VIM of SBP during the acute stage were nonsignificantly reduced with an increase in NIHSS levels. In contrast, DBP variability during the acute stage and both SBP and DBP variability during the subacute stage increased with the severity of baseline neurological deficits.
To elucidate whether indices of BP variability in the acute stage were associated with functional outcome, patients were divided into quartile groups according to each parameter of day-by-day SBP variability. However, all variability indices, SD, CV, VIM of SBP (Table 2 ) and DBP (Table II in the online-only Data Supplement), were not associated with functional outcome after adjusting for possible confounding factors. We further investigated the association between BP variability during the subacute stage and 3-month functional outcome (Table 3) . During the subacute stage (days 4-10 after onset), BP was measured once every morning. The number of BP measurements was 7 in 2494 patients (97.2%), 6 in 69 patients (2.7%), and 5 in 3 patients (0.1%). Consequently, SD, CV, VIM of SBP, and mean SBP level were significantly associated with poor functional outcome even after adjusting for 
Sensitivity Analysis
For the sensitivity analyses, we evaluated the association between SBP variability in the subacute stage and poor functional outcome in 1527 patients who did not receive antihypertensive agents during the subacute stage (Table 5) . In these patients, a significant association between SBP variability and clinical outcome remained. To exclude the possible involvement of stroke recurrence or death between 11 days and 3 months after stroke onset, the association was investigated in patients who survived without stroke recurrence until 3 months after onset (Table IV in the online-only Data Supplement). Until 3 months after onset, 81 patients had recurrent stroke and 11 died among them, whereas 44 patients died from other causes. Even after excluding these 125 patients, the association remained significant. Finally, we performed the same analysis in patients with minor stroke defined as stroke with onset NIHSS ≤4 (Table V in the online-only Data Supplement). When the analysis was performed in 1575 patients with minor stroke, the association between SD, CV, and VIM of BP and functional outcome was significant.
Discussion
The present study demonstrated that intraindividual variability of BP measured 3×/d during 1 to 3 days was not associated with 3-month functional outcome, but large day-by-day variability of BP measured once daily in the morning during 4 to 10 days after stroke was significantly associated with poor functional outcome at 3 months, independent of mean BP level, in hospitalized patients with acute ischemic stroke.
In the present study, the association between BP variability and functional outcome after ischemic stroke differed according to the time period from stroke onset. We found no association between BP variability in the acute poststroke period and 
Model 1 included age and sex. In model 2, body mass index, hypertension, diabetes mellitus, dyslipidemia, atrial fibrillation, estimated glomerular filtration rate, ischemic stroke subtype (cardioembolic or noncardioembolic infarction), infarct area (anterior or posterior circulation), antihypertensive agents administered during 1-3 days, the baseline National Institutes of Health Stroke Scale, and thrombolytic therapy were included in addition to model 1. Model 3 included the same variables as those in model 2 and mean BP. CI indicates confidence interval; CV, coefficient of variation; OR, odds ratio; SBP, systolic blood pressure; and VIM, variation independent of mean. by guest on June 25, 2017 http://stroke.ahajournals.org/ Downloaded from 3-month functional outcome. These data are supported by secondary analyses of 2 clinical trials, Controlling Hypertension and Hypotension Immediately Post-Stroke (CHHIPS) and Continue Or Stop post-Stroke Antihypertensives Collaborative Study (COSSACS), 10 but differed from that of other studies. [6] [7] [8] [9] Because the measurement of BP in our study was less frequent compared with other reports, BP variability with a long interval in the acute stage may be less indicative of functional outcome than rapid BP fluctuations. Furthermore, in the present study, greater SBP variability in the acute stage, measured by CV and VIM, was significantly associated with lower risk of poor functional outcome at 3 months after adjusting for age and sex, whereas these associations were attenuated and became nonsignificant by additional adjustment for baseline NIHSS and other risk factors ( Table 2 ). The precise reasons for these findings are unclear. However, odds ratios of the highest quartiles of CV and VIM remained low especially when baseline NIHSS is excluded from the multivariable model 2 (data not shown). Moreover, CV and VIM of SBP during the acute stage tended to be reduced with the severity of baseline neurological deficits, whereas BP variability during the subacute stage increased according to initial stroke severity ( Table I in the online-only Data Supplement). Such inverse correlation may confound the association between BP variability in the acute stage and functional outcome. By contrast, day-by-day BP variability during the subacute stage showed a significant association with functional outcome after ischemic stroke. No data have been reported on the association between day-by-day BP variability and functional outcome after acute ischemic stroke. Moreover, to our knowledge, only 1 prior study has assessed BP variability until the postacute phase in patients with ischemic stroke. Kang et al 12 suggested that BP variability during hospitalization (median of 34 measurements per patient within median interval from onset to discharge of 8.7 days) is related to functional outcome in patients with acute ischemic stroke. However, there are several differences between our studies. For example, in their study, reading-to-reading variability of BP was randomly measured during hospitalization, patients who had Model 1 included age and sex. In model 2, body mass index, hypertension, diabetes mellitus, dyslipidemia, atrial fibrillation, estimated glomerular filtration rate, ischemic stroke subtype (cardioembolic or noncardioembolic infarction), infarct area (anterior or posterior circulation), antihypertensive agents administered during 4-10 days, the baseline National Institutes of Health Stroke Scale, and thrombolytic therapy were included in addition to model 1. Model 3 includes the same variables as those in model 2 and mean BP. CI indicates confidence interval; CV, coefficient of variation; OR, odds ratio; SBP, systolic blood pressure; and VIM, variation independent of mean. by guest on June 25, 2017 http://stroke.ahajournals.org/ Downloaded from
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July 2015 previous history of stroke or were admitted later than 24 hours of onset were also included, and administration of antihypertensive drugs was not considered. We consider that daily BP variability at a fixed time is more reliable as a long-term variability index than random BP variability because daily BP values are less affected by circadian rhythm, the conditions of BP measurement, or patient status. The present study prospectively evaluated day-by-day BP variability during the subacute stage to determine its clinical significance. Nonetheless, our data indicate that day-by-day BP variability is a predictor of functional outcome after ischemic stroke. BP variability is a complex phenomenon produced by multiple factors. Various conditions, including increased sympathetic drive, reduced arterial and cardiopulmonary reflexes, impaired arterial compliance, humoral factors, blood viscosity, and emotional factors, may cause BP fluctuations. 15, 16 Previous studies suggest that impaired baroreflex is linked to worse clinical outcomes in patients with acute stroke. [30] [31] [32] Sykora et al 32 hypothesized that autonomic dysfunction in acute stroke may have unfavorable effects on outcomes via inadequate cerebral perfusion and impaired cerebral autoregulation, increased cardiovascular complications, and secondary brain injury because of inflammation, hyperglycemia, and blood-brain barrier disruption. These conditions may exacerbate brain ischemia or hamper recovery, leading to poor functional outcome after acute ischemic stroke. Further studies are required to elucidate the mechanisms for the association between day-by-day BP variation and functional outcome after stroke.
The FSR has several advantages for examining the effects of day-by-day BP variability on clinical outcomes after acute ischemic stroke. For example, FSR is a large-scale prospective hospital-based registry of patients with acute stroke, nurses measured in-hospital BP on schedules, the management and treatment of patients conformed to the Japanese Guidelines for the Management of Stroke, and possible confounding factors were extensively investigated and adjusted for. A potential limitation of the present study is that the small number of measurements used for evaluation of BP variability may lead to underestimation of the true association. Furthermore, patients with short hospital stay were excluded, leading to potential selection bias. In the present study, 243 patients had minor symptoms without significant disability before the onset, although further adjustment for prestroke functional status did not affect the results. Most subjects had rather minor strokes and the length of hospital stay was longer than that in Western countries. These may limit the generalizability. Table 3 . CI indicates confidence interval; CV, coefficient of variation; OR, odds ratio; SBP, systolic blood pressure; and VIM, variation independent of mean. 
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Methods
Patient database
One university hospital (Kyushu University Hospital) and six community hospitals (National Hospital Organization Kyushu Medical Center, National Hospital Organization FukuokaHigashi Medical Center, Fukuoka Red Cross Hospital, St. Mary's Hospital, Steel Memorial Yawata Hospital, and the Japan Labor Health and Welfare Organization Kyushu Rosai Hospital) located in Fukuoka Prefecture in southern Japan participated in the Fukuoka Stroke Registry (FSR). The FSR database includes demographic characteristics, medical history, pre-hospital, emergency, and in-hospital interventions, as well as patient status including activities of daily living, neurological symptoms, and laboratory data during hospitalization, in stroke patients registered in the FSR. The ethics review board at each participating institution approved the study design, and all patients or their proxies provided written informed consent to inclusion in the registry.
Stroke subtypes were classified as ischemic and hemorrhagic types. Ischemic stroke was further classified into four subtypes: lacunar, atherothrombotic, cardioembolic infarction, and unclassified (other determined or undetermined pathogenesis), based on the Classification of Cerebrovascular Disease III proposed by the National Institute of Neurological Disorders and Stroke 1 , as well as the diagnostic criteria of the Trial of Org 10172 in the Acute Stroke Treatment (TOAST) study 2 and the Cerebral Embolism Task Force 3 .
Parameters of blood pressure (BP) variability
Trained nurses measured the BP of patients resting in the supine position using an automated cuff or a mercury or aneroid sphygmomanometer. Among the 2566 patients assessed in this study, during the acute stage (days 1-3 after onset), BP was measured 10 times in 637 patients (24.8%), nine times in 823 patients (32.1%), eight times in 879 patients (34.3%), seven times in 170 patients (6.6%), six times in 47 patients (1.8%), five times in nine patients (0.4%), and four times in one (0.04%) patient. Three indices, the standard deviation (SD) of BP, coefficient of variation (CV) of BP (SD/mean×100), and variation independent of mean (VIM), were calculated using all readings of systolic BP (SBP) or diastolic BP (DBP) in each patient. VIM was calculated by M x × SD / mean x , where M was the average of mean SBP or DBP among the study subjects and x was derived from fitting curves, SD = k × mean Although 1372 (53.5%) patients had been treated with antihypertensive agents before admission, antihypertensives were discontinued in 747 patients during the acute stage, unless they were required as per guidelines. During the acute or subacute stage (days 1-10 after admission), antihypertensives were restarted or newly started in 414 patients. Thus, 1039 (40.5%) patients were treated with antihypertensive agents during the subacute stage (days 4-10 after admission).
Clinical assessment
The definitions of clinical assessment, such as hypertension, diabetes mellitus, dyslipidemia, atrial fibrillation, and estimated glomerular filtration rates, were the same as those previously reported. 4 Hypertension was defined as SBP ≥140 and/or DBP ≥90 mmHg before stroke, or a previous history of being medicated with antihypertensive drugs. Diabetes mellitus was defined as either an oral glucose tolerance test result of 75 g (diagnostic criteria of the World Health Organization in 1998) 5 or a medical history of diabetes. Dyslipidemia was defined as either low-or high-density lipoprotein-cholesterol or triglyceride levels of ≥3.62, <1.03, or ≥1.69 mmol/L, respectively, or currently being medicated with lipid-lowering drugs. Atrial fibrillation was diagnosed based on electrocardiographic findings upon admission or during hospitalization, or medical history. Estimated glomerular filtration rates (eGFR) were determined according to the equation proposed by the Japanese Society of Nephrology as follows: eGFR (mL/min/ OR: odds ratio, CI: confidence interval, DBP: systolic blood pressure, SD: standard deviation, CV: coefficient of variation, VIM: variation independent of mean. Model 1 included age and sex. In model 2, body mass index, hypertension, diabetes, dyslipidemia, atrial fibrillation, estimated glomerular filtration rate, ischemic stroke subtype (cardioembolic or non-cardioembolic infarction), infarct area (anterior or posterior circulation), antihypertensive agents administered during 4-10 days, the baseline NIHSS, and thrombolytic therapy were included in addition to model 1. Model 3 included the same variables as those in model 2 and mean blood pressure. OR: odds ratio, CI: confidence interval, SBP: systolic blood pressure, SD: standard deviation, CV: coefficient of variation, VIM: variation independent of mean. Model 1-3 included the same variables as those in Table II . SD: standard deviation, CV: coefficient of variation, VIM: variation independent of mean. Each variability index of BP (y axis) is plotted against mean BP (x axis) during the subacute stage. Only VIM showed no correlation with the mean value of both SBP and DBP.
